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TIMP-1 quartiles 01 (12 Q3 Q4 P (trend) 
LV mass, g 166 166 166 171 0.36 
LV wall thickness, cm 1.93 1.91 1.93 1.96 0.50 
LVESD, cm 2.94 3.01 2.99 3.03 0.03 
LVFS,% 37.9 37.0 37.0 36.3 0.003 
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Results: There were no differences in hemodynamic actions between groups. BNP 
increased urinary flow (from baseline 0.12 ~0.03 to low 0.76t0.82’ and high dose 
1.2OiO.96’ mifmin), but the effect of BNP+L was significantly (pcO.0001) higher (from 
0.12 kO.03 to 7.10+1.21’ and 6.25+0.94’ mUmin). Similarly, urinary sodium excretion 
(BNP: from 2.23*1.73 to 83.74+131.37’ and 164.66*171.05* mEq/min: BNP+L: from 
1.46+0.61 to 666.66i176.44’ and 606.41+65.96^ mEq/min) was significantly higher in 
BNP+L group (p<O.OOOl). GFR was maintained in both groups and plasma renin activity 
and aldosterone were not activated. 
Conclusion: BNP and BNP+L had similar beneficial hemcdynamic actions. Importantly, 
with a profound natriuretic and diuretic response with BNP+L, GFR was maintained with 
no activation of RAAS. Co-administration of BNP and a loop diuretic may be beneficial in 
preserving renal function and inhibiting the activation of aldosterone while maximizing 
natriuresis and diuresis. 
lar dyssynchrony (difference in LV and right ventricular (RV) mean phase angles) did not 
change from baseline to the final visit in the PL group (11 i17 vs 12 +9), while it 
improved in the cawedilol group (13 +17 vs 9 *14: p<O.Ol). The degree of intraventricu- 
lar dyssynchrony (std deviation of the mean phase angle) significantly improved for LV in 
the carvedilol group (54 i16 vs 51 *19: p=O.O4), but did not change for both the RV (41 
i12 vs 41 ill) and the LV (57 214 vs 56 +19) in the PL group, and for the RV in the 
carvedilol group (40 +14 vs 30 210). Conclusion: Treatment with calvedilol in patients 
with ischemic cardiomyopathy improves interventricular contractile synchrony between 
the LV and RV and intraventricular contraction synchrony of the LV. This is a new and 
additional mechanism by which cawedilol exerts beneficial effects on left ventricular 
function in ischemic heart failure. 
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1159MP-163 Tissue inhibitor of Metalloproteinases-1 in Plasma-- 
Relation to Left Ventricular Function and Geometry: The 
Framingham Heart Study 
JohanSundstrom, Emelia J. Benjamin, Jane Evans. Daniel Levy, Martin Larson, Douglas 
Sawyer, Deborah Siwik, Wilson Colucci. Peter W. Wilson, Ramachandran S. Vasan, 
FramIngham Heart Study, Framingham, MA 
Background: Tissue inhibitor of metalloproteinases-1 (TIMP-1) is a key regulator of car- 
diac extracellular matrix remodeling. Plasma TIMP-1 has been associated with hyperten- 
sion, left ventricular (LV) hyperirophy and heart failure in small, selected referral 
samples. Because of its role in LV remodeling, we examined the relations of total plasma 
TIMP-1 (free and in complex with metalloproteinases) to cardiac function and geometry 
in participants of the Framingham Heart Study. Methods: We studied 1014 participants 
(mean age 56 years, 59% women) free of heart failure and previous myocardial infarction 
who underwent routine echocardiography. 
Results: Plasma TIMP-1 was related positively to LV mass, LV wall thickness, end-sys- 
tolic diameter (LVESD), and left atrial diameter but inversely to fractional shortening (FS) 
in linear regression models adjusting for age, sex and height. Addiiional adjustment for 
weight, systolic blood pressure, antihypertensive treatment, diabetes, heart rate, smok- 
ing and total-IHDL-cholesterol ratio anew&d the relations of plasma TIMP-1 to LV 
mass, wall thickness, and left atrial diameter. In the latter models, inverse relations of 
plasma TIMP-1 to LVFS and direct relations to LVESD were maintained. 
Plasma TIMP-1 and LV measures 
LV measures are least squares means adjusted for age, sex, height, weight, systolic 
blood pressure, antihypertensive treatment, diabetes, heart rate, smoking and total-l 
HDL-cholesterol ratio 
Conclusion: In our large community-based sample free of heart failure and previous 
myocardial infarction, total plasma TIMP-1 was inversely related to LVFS independently 
of traditional cardiovascular risk factors, perhaps because it is a marker of LV remodel- 
ing. 
1159MP-164 Effect of Carvedilol to Correct Interventricular 
Dyssynchrony in Patients Wlth Chronic Heart Failure 
Due to lschemic Lefl Ventricular Systolic Dysfunction: 
Results of the CHRISTMAS Study 
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J~CODO Dalle Mule, John G F. Cleland. Dudley J. Pennel, Renzo Perelli. Gordon Murray, 
Andrew J S. Coats, Simon Ray, Avijlt Lahiri. Peter W. Macfarlane, Zvi Vered. City 
Hospital, Pieve di Cadore, Italy. Royal Brompton Hospital, London, United Kingdom 
Objective: To measure ventricular contractile synchrony in patients with ischemic left 
ventricular (LV) systolic dysfunction and to evaluate the effects of carvedilol on contrac- 
tile synchrony. Methods: We measured intraventricular conduction delay by means of 
phase analysis in 164 patients of the CHRISTMAS Study, who underwent radionuclide 
ventriculography (RNVG) at the time of randomization and at the end of the maintenance 
phase of treatment with cawedilol or placebo (PL). Results: The degree of intewentricu- 
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1159MP-165 Early Heightened inflammation Promotes Greater Left 
Ventricular Remodeling Following Anterior Myocardial 
Infarction 
Paul T. Vaitkus Ray S. Clemmer, Robert J. Anders, Johann Bauersachs, Jan B&as, Jiri 
Krupicka, University of Illinois et Chicago, Chicago, IL 
Background and Aims:Elevated inflammatory markers following MI predict poorer prog- 
nosis. The relationship of inflammation and LV remodeling has not been explored. Our 
hypothesis was that heightened inflammation would be related to greater LV dilation after 
MI. Methods:64 pts at 17 centers with a first anterior ST-elevation Ml completed sequen- 
tial contrast-enhanced echoes. Serum levels of IL-6 and TNF-a were measured 3-36 
hours (baseline) and 7 days after onset of Ml. Pts were divided into terciles of IL-6 and 
TNF-a for comparisons of the degree of increase in LVEDA from baseline to Day 
PB.Results:Baseline IL-6, but not TNF-a was associated with the degree of remodeling 
(see Fig). Pts in the highest tercile of IL-6 levels at baseline exhibited a greater degree of 
LV dilation. At day 7, most pts had undetectable IL-6 levels. Pt with elevated IL-6 at Day 
7 had greater remodeling (increase of LVEDA of 7 vs 2 cm2;p<.Ol)Conclusions: Height- 
ened inflammation early after Ml is associated with greater LV dilation, suggesting both a 
pathophysiologic link and a target for intervention. 
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1159MP-166 Left Ventricular Remodeling Is the Most Common 
Cause of Systolic Dysfunction After Acute Myocardial 
Infarction: Flndings From the Stent-PAMI Study 
Kishore J. Hariai, Cindy L. Grines, Steve Manichak. Judith A. Boura. Gregg W. Stone, 
David Cox, Bruce R. Brodie, William ONeill, William Beaumont Hospital, Royal Oak, Ml 
Background: Len ventricular systolic dysfunction (LVSD) develops after AMI in some 
patients despite reperfusion therapy and could be due to delayed or unsuccessful reper- 
fusion, silent ischemia. recurrent ischemic events, or left ventricular remodeling. The pur- 
pose of this study was to evaluate the frequency and etiology of LVSD following AMI 
treated with primary angioplasty (PCI). 
Methods: We studied 415 patients from the Stem-PAM1 study who underwent PCI with 
or without stent implantation, and had protocol-driven core lab assessment of LV ejection 
fraction (LVEF) acutely and 6-months later. We defined LVSD as a decrease in LVEF of 
210% at 6-months. We compared reperfusion delay, incidence of successful reperfusion 
(final stenosis < 30% with TIMI- flow), multivessel disease (reflecting propensity for 
ischemia at a distance), B-moo reinfarction @e-MI), and 6-mon target vessel revascular- 
i&ion (TVR) in patients with and without LVSD. 
Results: LVSD developed in 73 (16%) patients. Patients with LVSD were more likely to 
be male (69 vs 75%), had higher baseline LVEF (59 vs 53%, pcO.OOOl), but otherwise 
similar clinical and angiographic characteristics. Chest pain onset-to-door time (152 vs 
156 mini. door-to-balloon time (149 YS 173 min). successful reoerfuslon (61 vs 76%). 
multives~el disease (45 YS 50%): 6-mon re-MI (2.; vs 2.1%) and &non TVd (14 vs 12%) 
were similar lo>0.05 for all) in oatients with and without LVSD. At 6-months. LVEF was 
lower (47 vs 61%, p<O.OOOl), but LV end-diastolic volume (163+/-73 vs 140+/-62, 
p=O.OOS) and end-systolic volume (86+/-50 vs 55+/-32, pcO.0001) were higher in patients 
with LVSD. 
Conclusions: 1. LVSD develops unpredictably in a substantial minority of patients with 
AMI despite PCI. 2. Since LVSD is not related to delayed or unsuccessful reperfusion, 
multivessel disease, or recurrent ischemic events, it is likely caused by adverse LV 
remodeling. 3. Our findings support the routine use of ACE-inhibitors and beta-blockers 
for preservation of LV function after successful primary PCI. 
